Stage (next event)
Quarterly Sales (Approved)
March 12, 2021 (Est)
Catalyst Info & Data Links
TITLE: Gvoke® for Severe Hypoglycemia - Quarterly Sales (Approved)
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
March 21, 2021 (Est)
Quarter's sales: $9.4M (Q3/2020)
2020 Revenue guidance: NOT PROVIDED by company
11-09-2020 Third Quarter 2020 Financial Results
08-10-2020 Second Quarter 2020 Financial Results
05-07-2020 First Quarter 2020 Financial Results
2019: Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia. Clinical Diabetes, 37(4), 393-394.
Mechanism of Action
MECHANISM OF ACTION
Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.
There are 22.1M persons with diabetes in the US (T1D & T2D), where 6.2M currently use insulin
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post